Process Hazard Analysis (PHA) Services

Click Here to Chat With Our PHA Experts

Expert Hazard Analysis for Comprehensive Risk Management

aeSolutions provides detailed, rigorous Process Hazard Analysis services designed to proactively identify, evaluate, and mitigate process safety risks across diverse industries and facilities. Our PHA experts facilitate studies tailored to your specific operational context, whether for existing assets, capital projects, or management-of-change (MOC) scenarios.

Our extensive process hazard analysis capabilities include:

PHA Studies (Meeting regulatory compliance and/or client requirements)
Existing Facilities, Capital Projects, and MOCs
Fixed Facilities, Pipelines, Offshore, Transportation, and Specialty
Process PHAs, Procedural PHAs, and PHA Revalidations
Burner Management Systems, Chemicals, Oil and Gas, Manufacturing, Pharmaceuticals, and More

Hazard Analysis Service - aeSolutions.webp

Customized Methodologies for Specific Processes & Equipment

Recognizing that each facility and process presents unique hazards, aeSolutions applies industry-recognized methodologies matched to your specific operational environment. Our hazard analysis specialists select the most effective techniques to comprehensively assess risks, ensure regulatory compliance, and enhance safety performance.

Our hazard analysis methodologies include:

Methodologies Appropriate to the Specific Process and Equipment
- Hazard Identification (HAZID) and Hazard Register Development
- Hazard and Operability Analysis (HAZOP)
- What-If / Checklist Analysis
- Failure Modes and Effects Analysis (FMEA)
- Control System Hazard and Operability Analysis (CHAZOP)

With our tailored approach to hazard analysis, your organization can confidently manage risks, protect assets, and maintain a resilient safety culture.

Risk Matrix Development Support

aeSolutions can also help clients develop clear, defensible PHA risk matrices by facilitating management‑led workshops that define risk tolerability criteria and ensure consistent, risk‑based decision‑making across PHA and LOPA studies.